News and Reports | September 15, 2025
“Big pharma’s legal arguments against the Medicare Negotiation Program continue to prove baseless, and their high-priced lawyers have once again lost in court. With the first round of lower negotiated prices set to take effect in January, and the second round of drugs to be announced in the coming weeks, more than 9 million patients are finally on the cusp of long-overdue relief,” Merith Basey, executive director for the advocacy group Patients for Affordable Drugs (P4AD), said in a statement following the decision Thursday.
For P4AD, other patient and consumer groups and lawmakers who support the government’s ongoing efforts to bring down the costs of medications for seniors, the latest Third Circuit is considered another victory for patients.